What is Equillium?
Equillium operates at the intersection of advanced immunology and therapeutic innovation. The company is dedicated to the discovery and development of novel treatments for severe autoimmune and inflammatory diseases, a sector characterized by high barriers to entry and significant clinical complexity. By maintaining a rigorous focus on unmet medical needs, Equillium has established itself as a critical player in the biotechnology ecosystem, utilizing proprietary research to navigate the challenging path from laboratory discovery to clinical validation. Its market position is bolstered by a disciplined approach to drug development, ensuring that its therapeutic candidates are backed by robust scientific data and a clear path toward regulatory approval.
How much funding has Equillium raised?
Equillium has raised a total of $100M across 3 funding rounds:
Share Placement
$15M
Stock/Share Issuance
$50M
Stock/Share Issuance
$35M
Share Placement (2020): $15M with participation from Lincoln Park Capital Fund , LLC
Stock/Share Issuance (2025): $50M led by Adage Capital Management, Janus Henderson Investors, and Woodline Partners
Stock/Share Issuance (2026): $35M supported by RA Capital Management
Key Investors in Equillium
Adage Capital Management
Adage Capital Management is a money management firm primarily focused on S&P 500 assets. Adage is headquartered in Boston, Massachusetts.
Janus Henderson Investors
Janus Henderson is a global investment management firm that provides a broad range of investment solutions and advisory services to institutional investors, financial professionals, and individual clients.
Woodline Partners
San Francisco-based Woodline Partners LP is an investment firm implementing a market neutral equity strategy, focused on the global Healthcare and Technology sectors.
What's next for Equillium?
With the recent infusion of capital, Equillium is poised to enter a pivotal phase of its corporate lifecycle. The strategic allocation of these funds will likely prioritize the advancement of its lead clinical assets, potentially expanding the scope of its ongoing trials and enhancing its research infrastructure. As the company continues to navigate the complexities of the biotech sector, the focus will remain on achieving key clinical milestones that validate its therapeutic platform. Investors and stakeholders will be closely monitoring the firm's ability to translate this financial support into tangible clinical outcomes, which will be essential for long-term value creation and potential future commercialization efforts.
See full Equillium company page
